A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 in Healthy Participants
Latest Information Update: 21 May 2026
At a glance
- Drugs Taladegib (Primary) ; Nintedanib; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Endeavor BioMedicines
Most Recent Events
- 15 May 2026 Status changed from not yet recruiting to recruiting.
- 10 Mar 2026 New trial record